Creative Medical Technology (NASDAQ:CELZ) Raised to Hold at Wall Street Zen

Creative Medical Technology (NASDAQ:CELZ) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

CELZ has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday. Zacks Research raised Creative Medical Technology to a “hold” rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Creative Medical Technology Trading Up 5.4%

CELZ stock opened at $2.34 on Friday. The stock has a market capitalization of $6.04 million, a price-to-earnings ratio of -0.80 and a beta of 2.06. The firm’s 50-day moving average price is $3.25 and its two-hundred day moving average price is $2.98. Creative Medical Technology has a 12-month low of $1.69 and a 12-month high of $6.90.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, November 7th. The company reported ($0.48) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.48). Equities analysts predict that Creative Medical Technology will post -3.19 EPS for the current year.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Armistice Capital LLC purchased a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned 3.38% of Creative Medical Technology as of its most recent SEC filing. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.